San Fran biotech gets another blow to lead drug; Swiss biotech raises $49 million in Series A — with help from big venture
In the wake of Calithera Biosciences axing a third of its workforce in January over a failed Phase II trial with lead drug telaglenastat …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
